Table 3.
Clinical and treatment-related variables and impact on overall and grade ≥3 toxicity. NR: not reached; BED: biologically effective dose. Italic: variable type.
| Clinical and Treatment-related Variables | Overall Toxicity |
p | Grade ≥3 Toxicity |
p | ||
|---|---|---|---|---|---|---|
| No | Yes | No | Yes | |||
| Age (median 75 years, range 43–85) | ||||||
| <75 years | 27 (38%) | 11 (15%) | 0.81 | 37 (51%) | 1 (1%) | 0.53 |
| ≥75 years | 25 (35%) | 9 (12%) | 30 (42%) | 4 (6%) | ||
| Disease site | ||||||
| Juxtabronchial | 51 (71%) | 19 (27%) | 0.93 | 65 (90%) | 5 (8%) | 0.69 |
| Paraesophageal | 1 (1%) | 1(%) | 2 (2%) | 0 | ||
| Histotype | ||||||
| Adenocarcinoma | 36 (50%) | 18 (25%) | 0.73 | 50 (69%) | 4 (6%) | 0.97 |
| Squamous Cell Carcinoma | 14 (19%) | 4 (6%) | 17 (24%) | 1 (1%) | ||
| Timing of Metastatic Dissemination | ||||||
| Synchronous | 34 (47%) | 13 (18%) | 0.98 | 42 (58%) | 5 (8%) | 0.09 |
| Metachronous | 18 (25%) | 7 (10%) | 25 (34%) | 0 | ||
| Gross Tumor Volume (median 60 cc, range 7–400 cc) | ||||||
| <60 cc | 23 (32%) | 14 (19%) | 0.07 | 37 (51%) | 3 (5%) | 0.51 |
| ≥60 cc | 27 (37%) | 8 (12%) | 30 (42%) | 2 (2%) | ||
| Prior Chemotherapy | ||||||
| Naive | 32 (44%) | 13 (18%) | 0.79 | 41 (57%) | 4 (6%) | 0.29 |
| ≥ 1 line | 20 (28%) | 7 (10%) | 27 (37%) | 0 | ||
| BED (median 105, range 75–132 Gy10) | ||||||
| <75 Gy10 | 48 (66%) | 19 (27%) | 0.91 | 63 (86%) | 4 (6%) | 0.65 |
| ≥75 Gy10 | 4 (6%) | 1 (1%) | 5 (8%) | 0 | ||
| Overall Treatment Time | ||||||
| ≤1 week | 8 (11%) | 5 (8%) | 0.53 | 12 (17%) | 1 (1%) | 0.75 |
| >1 week | 44 (61%) | 15 (20%) | 56 (78%) | 3 (4%) | ||